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Subacute combined degeneration (SCD) is a rapidly progressive
myelopathy with a constellation of neurologic deﬁcits, including
progressive sensory abnormalities in the vibratory and proprio-
ceptive domains, ascending paresthesias, gait ataxia, hyper- or
hypo-reﬂexia, and, less commonly, motor weakness and loss of
bowel and bladder control [1,2]. SCD is a result of dorsal and lateral
spinal cord demyelination [3]. This form of myelopathy is
secondary to a cobalamin or vitamin B12 deﬁciency, dietary
insufﬁciency, malabsorption and/or, less commonly, excretion.
Pernicious anemia, also known as autoimmune gastritis, is a
common cause of vitamin B12 deﬁciency. Nitrous oxide (N2O)
exposure during recreational use or surgical intervention has also
been reported to convert B12 to B12 analogues, which are then
excreted in the urine, reducing B12 levels [3,4].
Up until now, much of the literature has presented the clinical
manifestations of SCD primarily in the context of nitrous oxide
(N2O) abuse and exposure. Conversely, we report on a patient with
a triple-insult SCD of the spinal cord, one insult secondary to non-
compliance with B12 replacement therapy for pernicious anemia,
one insult secondary to alcohol abuse, and one insult secondary to
prolonged recreational use of nitrous oxide.
2. Case report
A 38-year-old man was triaged at a tertiary care setting for
detoxiﬁcation and alcohol withdrawal. He presented acutely with
tremors, diaphoresis, insomnia, ataxia (progressive over the
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1877-0657/ 2015 Elsevier Masson SAS. All rights reserved.somatosensory perception, visual and auditory hallucinations,
paranoia, and cognitive impairments. On questioning, he described
copious alcohol consumption and nearly half a decade of N2O abuse
with a recent escalation. His medical history included pernicious
anemia, for which he was intermittently compliant with B12
injections, generalized anxiety disorder, major depressive disorder,
and social phobia. He was compliant with his psychiatric medica-
tions, but not with his psychotherapy, and had a suicide attempt two
decades prior.
Neurological ﬁndings were signiﬁcant for decreased vibratory
perception in his feet bilaterally; decreased pinprick and
temperature perception below his ankles bilaterally; dysmetria
on ﬁnger-to-nose testing; impaired tandem walking; low clear-
ance, wide-based gait; patellae hyper-reﬂexia; bilateral Babinski
sign; and a positive Romberg test. His mental status examination
revealed an illogical thought process, slow, halting speech,
depression, anxiety, paranoia and delusions consistent with an
acute, substance-induced psychotic disorder. Lab results revealed a
macrocytic anemia (hemoglobin 11.2 g/dL), low B12 (193 pg/mL),
elevated methylmalonic acid (324 nmol/L), hyperhomocysteine-
mia (213 mmol/L), and a mild transaminitis. His intrinsic factor
blocking antibody test conﬁrmed his pernicious anemia. The chest
X-ray and a non-contrast CT of the patient’s brain were negative for
acute processes. The patient was diagnosed with SCD.
Treatment included Librium, intramuscular B12 replacement
therapy, Risperidone, and resumption of his prior psychiatric
medication regimen. Five days into his hospitalization, he
remained a fall risk, continued to display dysmetria on the
ﬁnger-to-nose test, and still complained of visual hallucinations.
However, he was more articulate, reported decreased sleep
disturbances, and was stable for admission to acute inpatient
rehabilitation.
Upon admission to the inpatient rehabilitation unit, evaluation
his physical examination revealed a medium fall risk with a Berg
balance score of 23/56, poor dynamic standing balance, and fair
dynamic sitting balance. Contact guard assistance with straight
cane was required for both bed mobility and transfers, ambulation,
and stairway negotiation. For activities of daily living (ADL), he
required supervision for bathing, toileting, toilet transfers, and
dressing upper extremities; minimum assistance for bath trans-
fers; and moderate assistance for dressing lower extremities. In
terms of cognitive status, impairments included deﬁcits in delayed
recall, visuospatial and executive functions.
The patient underwent a three week acute inpatient rehabili-
tation course with intensive therapy consisting of two hours of
physical therapy and one hour of occupational therapy each day
ﬁve days per week. Physical therapy was used to retrain gait,
ambulation, transfers, bed mobility and use of an assistive device
and occupational therapy was used to retrain in ADLs, community
reintegration, and cognitive training. The rehabilitation therapy
helped the patient regained full sensory perception of his lower
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independence during bathing, toileting, toilet transfers, bath
transfers, bed mobility, dressing of upper/lower extremities and
ambulation on even surfaces. We noted improvements in other
areas of the assessment, however, his recovery was not complete.
The patient was still a low fall risk status with a Berg balance of 45/
56, showed impairments on dynamic balance testing, single leg
activities, and ambulation on uneven surfaces and negotiation of
ramps and stairs. Although his cognition appeared intact and
thought process became more logical, his thought content was still
impaired and contained thought insertions while his mood was
frustrated, anxious, depressed and blunted. He was subsequently
discharged to an inpatient substance abuse program.
3. Discussion
This is a unique case of SCD and acute psychosis secondary to a
triad of insults in a young patient. Pernicious anemia, chronic
alcoholism, and nitrous oxide abuse resulted in low B12 levels,
poor intestinal absorption of B12, and excretion of B12 analogues,
respectively. These factors prompted an early myelopathic onset
despite the fact that SCD classically occurs after the age of 60
[2,4,5]. With intensive rehabilitation, we witnessed a complete
resolution of sensory deﬁcits and numerous improvements in
function. However, some lingering deﬁcits in balance and thought
content compel us to suggest further research guidelines to
increase our understanding and improve our treatment of the
myelopathy.
Given its increased use today, N2O abuse and exposure should
be screened for in patients with a progressive myelopathy. Factors
that are positively correlated with complete resolution include a
younger age, male gender, early medical intervention, less severe
neurologic deﬁcits, and less spinal cord involvement. Older age,
sensory deﬁcits, anemia, positive Romberg and Babinski signs are
negatively correlated with complete resolution. Approximately
14% of SCD patients experience complete resolution and 86%
experience improvement with residual deﬁcits with B12 therapy
[1]. Considering his multiple negative correlates, including a longer
duration of illness, pernicious anemia, sensory deﬁcits, positive
Babinski sign and positive Romberg, a complete resolution was not
expected in our patient. Direct observance of B12 administration
and cessation of substance abuse halted the progression of
neurological damage while intensive rehabilitation therapy led
to signiﬁcant functional improvement. As demonstrated in this
case, rehabilitation can be used to assess progress, improve
recovery, and increase functionality in SCD and should be
considered an essential aspect of medical intervention.
Despite signiﬁcant improvements in patients who undergo
medical intervention, we have yet to achieve complete resolution
of neurological deﬁcits in SCD. The limited understanding of the
role that B12 deﬁciency plays in the pathogenesis of SCD may
contribute to this. Thus far, B12 deﬁciency is known to cause
myelin sheath swelling and vacuolation in SCD. The latest
hypothesis developed from studies on the gastrectomized rat
model of human SCD suggests that B12 deﬁciency disrupts the
normal balance of cytokines and growth factors that then
contributes to the pathogenesis of SCD. More speciﬁcally, B12
deﬁciency up-regulates spinal cord synthesis and cerebral spinal
ﬂuid (CSF) levels of myelinotoxic cytokines involved in systemic
inﬂammation such as tumor necrosis factor-alpha (TNF-a) and
soluble cluster of differentiation 40 ligand dyad (sCD40L), and a
myelinotoxin, nerve growth factor (NGF). Moreover, B12 deﬁcien-
cy down-regulates the anti-inﬂammatory cytokine interleukin-six
(IL-6), and the myelinotrophic growth factor, epidermal growth
factor (EGF) [4].Studies conﬁrm that elevated levels of TNF-a and reduced
levels EGF are found in the serum and CSF in patients with SCD. B12
replacement therapy corrects CNS cytokine and growth factor
abnormalities and results in the reappearance of normal myelin
[4,6]. In animal models, treatment with either IL-6, EGF, anti-TNF-
a, anti-CD40L or anti-NGF antibodies prevents the onset of
myelinolytic lesions [6].
Although the hypothesis has potential implications for the
future treatment of SCD, its limitations should be considered since
most of its supporting data stem from animal studies. Studies need
to be undertaken with patients to conﬁrm changes in IL-6, sCD40L,
and NGF levels. Further studies should test if treatment with TNF-a
antibody (anti-TNT- a), CD40L antibody (anti-CD40L), IL-6 and EGF
can prevent myelinolytic lesions in humans as they have in animals
and used as part of a treatment regimen that increases the
likelihood of complete resolution in patients with lesions
secondary to severe SCD. Further research is needed to deﬁne
precisely how changes in levels of cytokines and growth factors
precipitate SCD. Despite these limitations, the initial human data
provide evidence that a spinal tap for changes in cytokine and
growth factor levels can be used as part of a thorough diagnostic
work up.
Another unique feature of this case was the concurrent
diagnosis of an acute, substance-induced psychotic disorder. A
dearth of literature exists on acute psychosis in the context of both
N2O exposure or abuse and B12 deﬁciency. Patients with N2O
exposure or usage and B12 deﬁciency both present with similar
symptoms of memory loss, psychosis, hallucinations [7,8]. The
combination of the acute on chronic B12 deﬁciency and the N2O
abuse of our patient led to a compounded clinical picture including
severe hallucinations and paranoia, requiring medication and
psychiatric monitoring and treatment during his hospitalization.
4. Conclusion
In conclusion, physicians should be cognizant of the symp-
toms and pathogenesis of SCD. Recreational abuse of N2O has
been increasing, therefore, N2O induced SCD and/or psychosis
should be considered in a differential diagnosis when a patient
presents with a progressive myelopathy and/or mental status
changes. Physicians should screen for N2O abuse or exposure and
request laboratory tests of serum B12 levels, homocysteine,
methylmalonic acid and, if a spinal tap is warranted, CSF levels of
TNF-a and EGF. Also, further studies are needed to validate the
current growth factor and cytokine imbalance hypothesis in
humans and to test if anti-TNF-a, anti-CD40L, IL-6 and EGF can be
used as part of the medical intervention. Most importantly, early
B12 replacement and rehabilitation tailored towards the
patient’s functional and neuropsychiatric rehabilitation can
minimize the extent of the neurological damage. As we have
learned in this case, intensive rehabilitation can facilitate
recovery even in the most dire of circumstances. Our patient,
who delayed the presentation of his multifactorial SCD, was able
to regain complete sensation in his lower extremities and even
independence during ADLs.
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